| Literature DB >> 34079305 |
Yan Sun1,2, Lixin Yu1,2, Wei Gao1,2, Jinzhen Cai1,2, Wentao Jiang1,2, Wei Lu3, Yihe Liu1,2, Hong Zheng1,2.
Abstract
OBJECTIVE: This study aimed to investigate the colonization and prevalence of carbapenem-resistant Enterobacteriaceae (CRE) in pediatric liver transplant recipients and analyze the high-risk factors and prognosis of CRE infection.Entities:
Keywords: CRE; CT screening; anal swabs; carbapenem-resistant Enterobacteriaceae; intestinal colonization; liver transplantation
Year: 2021 PMID: 34079305 PMCID: PMC8164869 DOI: 10.2147/IDR.S304998
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Comparison of Basic Information of Two Groups of Liver Transplant Recipients
| Non-CRE Infection Group, n=139(91.4%) | CRE Infection Group, n=13(8.6%) | p | |
|---|---|---|---|
| Age(Mon) | 7(6–10) | 7(5–10.5) | 0.318 |
| Gender(M) | 59(42.4%) | 6(46.2%) | 0.96 |
| Preoperative hospitalization time (d) | 10(3–23) | 21(4–36) | 0.103 |
| Preoperative ICU stay | 0 | 0 | 0.543 |
| Primary disease(BA) | 126(90.6%) | 12(92.3%) | 0.810 |
| PELD score | 17(10–23) | 12(7–21) | 0.274 |
| Combined heart disease | 48(34.5%) | 5(38.5%) | 0.776 |
| Pre-operative Gelsemium | 65(46.8%) | 8(61.5%) | 0.308 |
| Preoperative antibiotic exposure | 57(41%) | 9(69.2%) | 0.05 |
| Cephalosporin III | 35(27.1%) | 6(46.2%) | 0.193 |
| Carbapenems | 35(27.1%) | 3(23.1%) | 0.867 |
| Anti-positive bacteria antimicrobial | 17(13.2%) | 3(23.1%) | 0.269 |
| Pre-operative pneumonia | 26(20.2%) | 4(30.8%) | 0.296 |
| Pre-operative cholangitis | 20(15.5%) | 2(15.4%) | 0.753 |
| Pre-operative sepsis | 10(7.8%) | 4(30.8%) | 0.0005 |
| Pre-operative peritonitis | 13(2.3%) | 0 | 0.249 |
| Pre-operative CMV infection | 5(3.9%) | 4(30.8%) | <0.0001 |
| Previous CRE infection before surgery | 1(0.7%) | 4(30.8%) | <0.001 |
| Preoperative internal indwelling central venous catheter | 20(14.4%) | 2(15.4%) | >0.05 |
Abbreviation: BA, biliary atresia.
Comparison of Surgical Data Between Two Groups of Liver Transplant Recipients
| Non-CRE Infection Group, n=139(91.4%) | CRE Infection Group, n=13(8.6%) | p | ||
|---|---|---|---|---|
| Surgical Procedure | DBD/DCD liver transplant | 32(23%) | 5(38.5%) | 0.0516 |
| Parental liver transplant | 106(76.3%) | 7(53.8%) | ||
| Assisted liver transplantation | 1(0.7%) | 1(7.7%) | ||
| Surgery time | 7.8±1.5 | 8.8±1.3 | 0.032 | |
| Intraoperative bleeding volume | 300(200–400) | 400(275–500) | 0.045 | |
| Intraoperative red blood cell transfusion volume | 2(2–3) | 3(2–4.5) | 0.255 | |
Abbreviations: DBD, brain-dead donor; DCD, cardiac-death donor.
Comparison Between
| CRE Colonization Group n=44(28.9%) | Non-CRE Colonization Group n=108(71.1%) | p | |
|---|---|---|---|
| Age(Mon) | 7.4(4–19) | 8.1(5–36) | 0.318 |
| Gender(M) | 21(47.7%) | 44(40.7%) | 0.472 |
| Primary disease(BA) | 40(90.9%) | 98(90.7%) | 0.974 |
| PELD score | 17(10–23) | 12(7–21) | 0.274 |
| Preoperative hospitalization time (d) | 23(4–70) | 11(4–34) | 0.023 |
| Pre-operative Gelsemium | 28(63.9%) | 45(41.7%) | 0.02 |
| Preoperative antibiotic exposure | 27(61.4%) | 39(36.1%) | 0.007 |
| Pre-operative CRE infection | 4(9.1%) | 1(0.9%) | 0.025 |
| Preoperative internal indwelling central venous catheter | 7(15.9%) | 15(13.9%) | 0.801 |
| Surgery time (h) | 7.8±1.5 | 8.8±1.3 | 0.132 |
| Intraoperative bleeding volume (mL) | 320(200–400) | 370(275–500) | 0.055 |
| ICU treatment time (d) | 7.7(3–21) | 8(4–14) | 0.203 |
| Unplanned surgery | 9(20.5%) | 6(5.6%) | 0.013 |
| Postoperative blood purification | 2(4.5%) | 1(0.9%) | 0.201 |
| Postoperative mechanical ventilation >24h | 5(11.4%) | 5(4.6%) | 0.154 |
Postoperative Comparison of Two Groups of Liver Transplant Recipients
| Non-CRE Infection Group, n=139(91.4%) | CRE Infection Group, n=13(8.6%) | p | |
|---|---|---|---|
| Postoperative occurrence of unplanned surgery | 11(7.9%) | 4(30.7%) | 0.026 |
| Liver dysfunction | |||
| Primary non-functional | 1(0.7%) | 0 | >0.05 |
| Acute rejection | 6(4.3%) | 1(7.7%) | 0.472 |
| Drug-induced liver damage | 4(2.9%) | 0 | >0.05 |
| Liver dysfunction due to CMV infection | 3(2.2%) | 0 | >0.05 |
| Postoperative liver support therapy | 1(0.7%) | 1(7.7%) | 0.164 |
| Postoperative acute kidney injury | 35(25.2%) | 3(23.1%) | >0.05 |
| Postoperative renal replacement therapy | 1(0.7%) | 0 | >0.05 |
| Postoperative mechanical ventilation >24h | 7(5%) | 3(23.1%) | 0.042 |
| Pre-ICU CRE colonization | 17(12.2%) | 9(69.2%) | <0.001 |
| Post-ICU CRE colonization | 15(10.8%) | 3(23.1%) | 0.389 |
| Infectious complications | |||
| Pneumonia | 6(4.3%) | 3(23.1%) | 0.031 |
| Abdominal cavity infection | 32(23%) | 3(23.1%) | >0.05 |
| Sepsis | 5(3.6%) | 0 | >0.05 |
| CMV/EBV | 36(25.9%) | 4(30.8%) | 0.959 |
| Skin soft tissue infections | 1(0.7%) | 0 | >0.05 |
| Vascular complications | |||
| Stenosis of the portal anastomosis | 7(5%) | 1(7.7%) | 0.52 |
| Hepatic artery occlusion | 1(0.7%) | 1(7.7%) | 0.164 |
| Outflow tract obstruction | 2(1.4%) | 0 | >0.05 |
| Biliary complications | |||
| Gall bladder | 6(4.3%) | 0 | >0.05 |
| Biliary stenosis | 5(3.6%) | 0 | >0.05 |
| Intestinal fistula | 1(0.7%) | 2(15.4%) | 0.019 |
| Intestinal obstruction | 1(0.7%) | 0 | >0.05 |
| PCT level one month after surgery | 0.92(0.4–3.7) | 4.5(1.7–22) | 0.004 |
| FK506 concentration one month after surgery | 7.6±1.8 | 6.6±2.6 | 0.079 |
Note: EBV for human herpes virus type 4 (HIV-IV).
Multifactorial Analysis of CRE Infection
| B | Standard Error | Wald | Degree of Freedom | p | Exp(B) | 95% CI | |
|---|---|---|---|---|---|---|---|
| Pre-operative CRE infection | 11.703 | 4.758 | 6.050 | 1 | 0.014 | 61.333 | 6.194–607.3 |
| Pre-ICU CRE colonization | 3.833 | 1.163 | 10.865 | 1 | 0.001 | 46.192 | 4.729–451.182 |
Figure 1Survival curves of CRE infection group and non-CRE infection group after operation.